Key facts
- This page summarizes Howard G. Welgus's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 19 Oct 2026, 16:49.
Howard G. Welgus - 15 Oct 2026 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)
- Reporting relationship
- Director
- Issuer ticker
- ARQT
- Reported as of
- 15 Oct 2026
- Net transaction value
- -$127,325
- SEC form
- 4
- Accepted by SEC
- 19 Oct 2026, 16:49:50 UTC
- Prior SEC filing
- 17 Sep 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Howard G. Welgus filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 19 Oct 2026.
Change
- Previous filing in this sequence was filed on 17 Sep 2026.
- Current net transaction value: -$127,325.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001801050
Primary reporting owner
Welgus Howard G.
- Relationship
- Director
- Address
- C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE
- Signature
- /s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus
- Signature date
- 19 Oct 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARQT
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +822
- Change %
- +2.3%
- Price
- $6.52*
- Shares after
- 36,663
- Date
- 15 Oct 2026
- Ownership
- Direct
- Footnotes
- F1
ARQT
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,018
- Change %
- +2.8%
- Price
- $7.51*
- Shares after
- 37,681
- Date
- 15 Oct 2026
- Ownership
- Direct
- Footnotes
- F1
ARQT
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +2,254
- Change %
- +6%
- Price
- $8.63*
- Shares after
- 39,935
- Date
- 15 Oct 2026
- Ownership
- Direct
- Footnotes
- F1
ARQT
transaction
Common Stock
Sale
- Transaction value
- $127,325
- Shares
- -4,728
- Change %
- -12%
- Price
- $26.93
- Shares after
- 35,207
- Date
- 15 Oct 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARQT
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -822
- Change %
- -13%
- Price
- $0.000000*
- Shares after
- 5,752
- Date
- 15 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 822
- Exercise price
- $6.52
- Footnotes
- F1, F2
ARQT
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -1,018
- Change %
- -12%
- Price
- $0.000000*
- Shares after
- 7,126
- Date
- 15 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,018
- Exercise price
- $7.51
- Footnotes
- F1, F2
ARQT
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -2,254
- Change %
- -12%
- Price
- $0.000000*
- Shares after
- 15,778
- Date
- 15 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,254
- Exercise price
- $8.63
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.
Footnote F2
The option is fully vested.